Piramal Pharma Limited (BOM:543635)
225.60
+1.10 (0.49%)
At close: Apr 1, 2025
Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 299.00 billion. The enterprise value is 342.78 billion.
Market Cap | 299.00B |
Enterprise Value | 342.78B |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
Earnings Date | May 9, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +8.30% |
Shares Change (QoQ) | -7.69% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 607.58M |
Valuation Ratios
The trailing PE ratio is 768.63.
PE Ratio | 768.63 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 8.02 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 881.17 |
EV / Sales | 3.83 |
EV / EBITDA | 23.20 |
EV / EBIT | 47.79 |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 0.61 |
Debt / EBITDA | 3.40 |
Debt / FCF | n/a |
Interest Coverage | 1.51 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | 3.24% |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | 13.32M |
Profits Per Employee | 57,896 |
Employee Count | 6,719 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +83.49% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +83.49% |
50-Day Moving Average | 215.70 |
200-Day Moving Average | 215.50 |
Relative Strength Index (RSI) | 58.38 |
Average Volume (20 Days) | 520,044 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 89.49 billion and earned 389.00 million in profits. Earnings per share was 0.29.
Revenue | 89.49B |
Gross Profit | 53.51B |
Operating Income | 6.48B |
Pretax Income | 3.69B |
Net Income | 389.00M |
EBITDA | 13.71B |
EBIT | 6.48B |
Earnings Per Share (EPS) | 0.29 |
Balance Sheet
The company has 4.08 billion in cash and 47.86 billion in debt, giving a net cash position of -43.78 billion.
Cash & Cash Equivalents | 4.08B |
Total Debt | 47.86B |
Net Cash | -43.78B |
Net Cash Per Share | n/a |
Equity (Book Value) | 79.07B |
Book Value Per Share | 59.51 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 59.79%, with operating and profit margins of 7.25% and 0.43%.
Gross Margin | 59.79% |
Operating Margin | 7.25% |
Pretax Margin | 4.13% |
Profit Margin | 0.43% |
EBITDA Margin | 15.32% |
EBIT Margin | 7.25% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 0.05%.
Dividend Per Share | 0.11 |
Dividend Yield | 0.05% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -8.30% |
Shareholder Yield | -8.25% |
Earnings Yield | 0.13% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |